Protalix BioTherapeutics (NYSE:PLX) Rating Lowered to “Buy” at StockNews.com

StockNews.com cut shares of Protalix BioTherapeutics (NYSE:PLX) from a strong-buy rating to a buy rating in a research note released on Thursday.

Separately, HC Wainwright boosted their price target on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

Protalix BioTherapeutics Stock Performance

Shares of PLX opened at $2.49 on Thursday. The company’s fifty day moving average is $2.40 and its 200 day moving average is $1.76. Protalix BioTherapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $2.76. The stock has a market capitalization of $194.30 million, a PE ratio of -19.15 and a beta of 0.72.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Y Intercept Hong Kong Ltd purchased a new position in Protalix BioTherapeutics during the fourth quarter worth $35,000. PFG Investments LLC purchased a new position in Protalix BioTherapeutics during the fourth quarter worth $39,000. Cubist Systematic Strategies LLC boosted its stake in Protalix BioTherapeutics by 24.1% during the fourth quarter. Cubist Systematic Strategies LLC now owns 29,307 shares of the company’s stock worth $55,000 after buying an additional 5,686 shares during the period. XTX Topco Ltd purchased a new position in Protalix BioTherapeutics during the third quarter worth $36,000. Finally, Prudential Financial Inc. purchased a new position in Protalix BioTherapeutics during the 4th quarter valued at $68,000. 16.53% of the stock is owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.